AR042015A1 - GENETIC MARKER RELATED TO THE CAPACITY OF PRODUCING SULFHYDIC ACID FOR DAMAGED BACTERIAL VACCINES - Google Patents

GENETIC MARKER RELATED TO THE CAPACITY OF PRODUCING SULFHYDIC ACID FOR DAMAGED BACTERIAL VACCINES

Info

Publication number
AR042015A1
AR042015A1 ARP030104114A ARP030104114A AR042015A1 AR 042015 A1 AR042015 A1 AR 042015A1 AR P030104114 A ARP030104114 A AR P030104114A AR P030104114 A ARP030104114 A AR P030104114A AR 042015 A1 AR042015 A1 AR 042015A1
Authority
AR
Argentina
Prior art keywords
ability
mutation
bacteria
bacterium
producing
Prior art date
Application number
ARP030104114A
Other languages
Spanish (es)
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Publication of AR042015A1 publication Critical patent/AR042015A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen bacterias genéticamente alteradas atenuadas deficientes en la capacidad de producir sulfuro de hidrógeno (H2S) para utilizar como vacunas vivas o vectores vivos que pueden administrarse a un organismo huésped para proporcionar inmunidad frente a una enfermedad o para proporcionar otro producto o función genética beneficiosa. Las bacterias genéticamente alteradas de la presente pueden distinguirse fácilmente de otras bacterias mediante un fenotipo H2S negativo cuando se incuba en o de otro modo se contacta con un medio utilizado para detectar la producción de H2S en bacterias. Reivindicación 1: Una bacteria genéticamente alterada deficiente en la capacidad de producir sulfuro de hidrógeno (H2S) que comprende: (a) una primera mutación la cual atenúa la virulencia de dicha bacteria hacia un organismo huésped, donde dicha primera mutación no afecta la capacidad de dicha bacteria de producir H2S, y (b) una segunda mutación, donde dicha mutación torna a la bacteria deficiente en la capacidad de producir H2S.Attenuated genetically altered bacteria deficient in the ability to produce hydrogen sulfide (H2S) to be used as live vaccines or live vectors that can be administered to a host organism to provide immunity against a disease or to provide another beneficial genetic product or function are described. Genetically altered bacteria of the present can be easily distinguished from other bacteria by a negative H2S phenotype when incubated in or otherwise contacted by a means used to detect the production of H2S in bacteria. Claim 1: A genetically altered bacterium deficient in the ability to produce hydrogen sulfide (H2S) comprising: (a) a first mutation which attenuates the virulence of said bacterium towards a host organism, wherein said first mutation does not affect the ability of said bacterium producing H2S, and (b) a second mutation, wherein said mutation makes the bacterium deficient in the ability to produce H2S.

ARP030104114A 2002-11-08 2003-11-07 GENETIC MARKER RELATED TO THE CAPACITY OF PRODUCING SULFHYDIC ACID FOR DAMAGED BACTERIAL VACCINES AR042015A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42495202P 2002-11-08 2002-11-08

Publications (1)

Publication Number Publication Date
AR042015A1 true AR042015A1 (en) 2005-06-08

Family

ID=33551205

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104114A AR042015A1 (en) 2002-11-08 2003-11-07 GENETIC MARKER RELATED TO THE CAPACITY OF PRODUCING SULFHYDIC ACID FOR DAMAGED BACTERIAL VACCINES

Country Status (3)

Country Link
AR (1) AR042015A1 (en)
AU (1) AU2003304255A1 (en)
WO (1) WO2005001069A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095180A2 (en) * 2005-03-10 2006-09-14 Ultra Biotech Limited Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US8465755B2 (en) 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
US8889121B2 (en) 2010-01-22 2014-11-18 The Arizona Board Of Regents For An On Behalf Of Arizona State University Bacterium comprising a regulated rfaH nucleic acid
CN101962625A (en) * 2010-04-29 2011-02-02 河南科技大学 Salmonella choleraesuis gene deletion mutant without resistant marker and vaccine thereof
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
CN104651288A (en) * 2015-01-07 2015-05-27 四川农业大学 Pasteurella multocida attenuated strain deficient in crp as well as construction method and application of attenuated strain
CN104560854B (en) * 2015-01-07 2018-03-02 四川农业大学 Lack phoP eggs crack detection attenuated strain and its construction method and application

Also Published As

Publication number Publication date
WO2005001069A1 (en) 2005-01-06
AU2003304255A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
AR042015A1 (en) GENETIC MARKER RELATED TO THE CAPACITY OF PRODUCING SULFHYDIC ACID FOR DAMAGED BACTERIAL VACCINES
Mobley et al. Helicobacter pylori: physiology and genetics
Salanitro et al. Isolation, culture characteristics, and identification of anaerobic bacteria from the chicken cecum
Freundt Culture media for classic mycoplasmas
ES2061519T3 (en) PROCEDURE FOR THE PRODUCTION OF EICOSAPENTAENOIC ACID.
MX2011000793A (en) Methods, systems and compositions for increased microorganism tolerance to and production of 3-hydroxypropionic acid (3-hp).
AR045813A1 (en) METHOD FOR OBTAINING A BIOLOGICALLY ACTIVE BOTULINIC TOXIN, COMPOSITION THAT INCLUDES CLOSTRIDIUM BOTULINUM AND A CROP MEANS TO PRODUCE A BOTULINAL TOXIN THROUGH SUCH METHOD AND METHOD FOR PREPARING A PHARMACEUTICALLY COMPREHENSIVE PRODUCT COMPOSITION
ES2089232T3 (en) 5-ENOLPIRUVILSIQUIMATO-3-FOSFATO TOLERANT SYNTHASES OF GLYPHOSATE.
RU2008147883A (en) APPLICATION OF LACTIC ACID BACTERIA TO REDUCE CHILDREN'S COLIC
KR101589465B1 (en) Use of bifidobacterium breve cbt br3 strain for promoting growth and nutraceutical composition for promoting growth comprising the same
GB0103301D0 (en) Culture of crypthecodinium cohnii and microorganisms derived therefrom
KR20140014369A (en) Rapid sterility microassay
CN105925561A (en) Breeding method of strong-acid resistant lactic acid bacteria strain
CN102061272A (en) Lactobacillus salivarius SIL1 and application thereof
CN106282075A (en) A kind of fluid medium for cultivating haemophilus parasuis
Sánchez-Jiménez et al. Distribution of pathogenicity islands among Colombian isolates of Salmonella
DK1831349T3 (en) Method of cultivating bacteria to deliver bioactive compounds to the intestine of ruminants
TW201538722A (en) Probiotic strain producing hyaluronic acid and uses thereof
BRPI0401947A (en) Method for producing an l-amino acid and bacteria
ES2365798T1 (en) GENETICALLY PURIFIED GELAN RUBBER.
CN103992962A (en) Streptococcusmutans rnc gene mutant strain and application thereof
Raut et al. Isolation and characterization of protease producing bacteria from upper respiratory tract of wild chicken
Kim et al. Probiotic properties and adsorption of Enterococcus faecalis PSCT3-7 to vermiculite
CN201813935U (en) Bactericidal shoes
CN106924229B (en) Application of the phloretin in preparation treatment chicken necrotizing enterocolitis drug

Legal Events

Date Code Title Description
FB Suspension of granting procedure